The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
DNA damage response and repair (DDR) gene mutations and correlation with tumor mutation burden (TMB) in non-small cell lung cancer (NSCLC).
 
Hirva Mamdani
Consulting or Advisory Role - Tempus
 
Jerry Chen
No Relationships to Disclose
 
Seongho Kim
No Relationships to Disclose
 
Yahya Ibrahim
No Relationships to Disclose
 
Mohammad Fahad Bin Asad
No Relationships to Disclose
 
Jorge J. Nieva
Stock and Other Ownership Interests - Epic Sciences
Consulting or Advisory Role - AstraZeneca; Genentech/Roche; Western Oncolytics
Research Funding - Merck
Patents, Royalties, Other Intellectual Property - Patent Pending - movement and unexpected healthcare encounters
 
Rebecca Feldman
Employment - Caris Life Sciences
 
Abdul Rafeh Naqash
No Relationships to Disclose
 
Stephen V. Liu
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene; Genentech; HERON; Lilly; Pfizer; Regeneron; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca; Bayer; Blueprint Medicines; Clovis Oncology; Corvus Pharmaceuticals; Esanex; Genentech/Roche; Lilly; Lycera; Merck; Molecular Partners; OncoMed; Pfizer; Threshold Pharmaceuticals
 
Patrick C. Ma
Stock and Other Ownership Interests - Cymeta Biopharmaceutical
Consulting or Advisory Role - Apollomics; AstraZeneca; Takeda
Speakers' Bureau - AstraZeneca; Bayer; Bristol-Myers Squibb; Merck; Takeda
Research Funding - Abbvie (Inst); Apollomics (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Cymeta Biopharmaceutical (Inst); EpicentRx (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); OncoMed (Inst); Pfizer (Inst); Tesaro (Inst); Xcovery (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences
 
David Craig Portnoy
Employment - CNS Healthcare (I)
Research Funding - Lilly
 
Hossein Borghaei
Honoraria - Axiom Biotechnologies; Bristol-Myers Squibb; Celgene
Consulting or Advisory Role - Abbvie; AstraZeneca; BioNTech; Boehringer Ingelheim; Bristol-Myers Squibb; Cantargia AB; Celgene; EMD Serono; Genentech; Genmab; Lilly; Merck; Novartis; Pfizer; Regeneron; Trovagene
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Lilly; Merck; Novartis
Other Relationship - Takeda; University of Pennsylvania
 
Nagla Fawzy Abdel Karim
Stock and Other Ownership Interests - Abbott Biotherapeutics (I)
Consulting or Advisory Role - Alexion Pharmaceuticals; Bayer; Immunocore
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Celgene; Genentech; Merck; Novartis; Pfizer
Research Funding - Pfizer
Expert Testimony - Exosome Diagnostics
 
Yanis Boumber
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Caris Life Sciences; Takeda
 
Ari M. Vanderwalde
Honoraria - AstraZeneca
Consulting or Advisory Role - Bristol-Myers Squibb; Caris Life Sciences; Compugen; Genentech/Roche; Immunocore
Research Funding - Amgen (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Polynoma (Inst); Replimune (Inst)
 
Alexander I. Spira
Honoraria - AstraZeneca/MedImmune; CytomX Therapeutics; Merck
Consulting or Advisory Role - Array BioPharma (Inst)
Research Funding - Abbvie (Inst); Archer (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Ignyta (Inst); Incyte (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Trovagene (Inst)
 
Shadia Ibrahim Jalal
Research Funding - AstraZeneca/MedImmune